Results 1 to 10 of about 447,382 (156)
Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni [PDF]
Pharmaceuticals, 2021 The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, a disease of great global public health significance. Praziquantel is the only drug available to treat schistosomiasis and there is an urgent demand for new ...
Raquel Porto +9 more
doaj +2 more sources
Risk of antidepressant initiation among users of cardiovascular agents and metformin. [PDF]
Pharmacology Research & Perspectives, 2023 Cardiovascular disease and diabetes are risk factors for depression, yet the relationship between the drug treatments for these diseases and the risk of antidepressant initiation remains unclear.
Ivana Bojanić +6 more
doaj +2 more sources
Acute poisoning by cardiovascular agents [PDF]
Vojnosanitetski Pregled, 2003 In order to determine the frequency, severity of poisoning, and the efficacy of the applied therapeutic measures, retrospective study of 391 patients treated for acute drug poisoning was performed during one-year period at the Clinic for Emergency and ...
Vučinić Slavica +5 more
doaj +3 more sources
Cardiovascular effects of immunosuppression agents
Frontiers in Cardiovascular Medicine, 2022 Immunosuppressive medications are widely used to treat patients with neoplasms, autoimmune conditions and solid organ transplants. Key drug classes, namely calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and purine synthesis ...
Aly Elezaby +4 more
doaj +3 more sources
One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing [PDF]
MoleculesChronic wound treatments pose a challenge for healthcare worldwide, particularly for the people in developed countries. Chronic wounds significantly impair quality of life, especially among the elderly.
Anna Gościniak +4 more
doaj +2 more sources
Journal of Cardiovascular Development and Disease, 2022 Ischemic cardiovascular diseases have a high incidence and high mortality worldwide. Therapeutic advances in the last decades have reduced cardiovascular mortality, with antithrombotic therapy being the cornerstone of medical treatment.
Ignacio Barriuso +2 more
doaj +3 more sources
Cardiovascular Toxicities of Immunosuppressive Agents
American Journal of Transplantation, 2002 Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. Many of the current immunosuppressive drugs are associated with an increase of one or more risk factors for the development of atherosclerosis.
exaly +3 more sources
Cardiovascular and Cardioprotective Agents in 2021
Current Pharmaceutical Design, 2021 Manfredi Rizzo
exaly +3 more sources
Cardiovascular Complications of Acetylcholinesterase Inhibitors in Patients with Alzheimer’s Disease: A Narrative Review [PDF]
Annals of Geriatric Medicine and Research, 2021 While acetylcholinesterase inhibitors are used to treat a wide range of patients with Alzheimer’s disease, acetylcholinesterase inhibitor use has also been associated with a variety of cardiovascular complications, including bradycardia and syncope ...
Sara Young, Enoch Chung, Michael A. Chen
doaj +1 more source
Anatolian Journal of Cardiology, 2023 Background: Elderly comprises a specific group due to possible alterations in the effects of drugs and comorbidities. We aimed to identify for the first time the characteristics and rates regarding the inappropriate prescriptions of cardiovascular system
Mehmet Tevfik Kitapçı +5 more
doaj +1 more source